GlassScriptPhysician profile
Dongxin Liu
NPI 1114152220
$4,815.28
in general payments reported to CMS, 2019-2025
44 companies · $826 in 2025
The $826 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,190 · 2020: $194 · 2021: $224 · 2022: $159 · 2023: $817 · 2024: $1,406 · 2025: $826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,930 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,930.24 |
| Education | $118.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $375.47 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $340.13 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Celgene Corporation | $269.97 | 2023-2025 | Pomalyst, Opdualag, Reblozyl |
| Novartis Pharmaceuticals Corporation | $269.29 | 2019-2025 | |
| Lilly USA, LLC | $240.56 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Merck Sharp & Dohme LLC | $214.89 | 2019-2024 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $197.73 | 2019-2024 | |
| Myriad Genetic Laboratories, INC. | $194.52 | 2024 | Myrisk |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.96 | 2019-2023 | Gilotrif |
| Janssen Biotech, INC. | $184.72 | 2019-2025 | Rybrevant |
| Tempus Ai, INC | $175.52 | 2024-2025 | Xt Cdx |
| Seagen INC. | $157.07 | 2021-2023 | Padcev, Adcetris |
| Pharmacyclics LLC, An Abbvie Company | $140.81 | 2019 | |
| Amgen INC. | $125.32 | 2022-2023 | Lumakras, Xgeva, Vectibix |
| Pharmacosmos Therapeutics INC. | $123.72 | 2024-2025 | Monoferric |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $122.56 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $119.71 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $111.45 | 2022-2025 | Xarelto, Darzalex, Talvey |
| Astellas Pharma US INC | $102.40 | 2019-2025 | Xospata, Xtandi, Vyloy |
| Incyte Corporation | $95.50 | 2023-2024 | Jakafi, Monjuvi |
| Puma Biotechnology, INC. | $95.08 | 2023-2025 | Nerlynx |
| Genzyme Corporation | $90.73 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $89.57 | 2024-2025 | Libtayo |
| Sobi, INC | $88.75 | 2024-2025 | |
| Emd Serono, INC. | $85.08 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $81.00 | 2024-2025 | Ultomiris |
| Genentech USA, INC. | $71.01 | 2019 | |
| Azurity Pharmaceuticals, INC. | $51.98 | 2024-2025 | Vivimusta, Danziten |
| Daiichi Sankyo INC. | $50.52 | 2020-2024 | Enhertu |
| Tersera Therapeutics LLC | $40.76 | 2019 | |
| Pharmaessentia USA Corporation | $34.69 | 2023 | Besremi |
| Exelixis INC. | $33.86 | 2019 | |
| Novocure INC. | $26.11 | 2025 | Optune Gio |
| Array Biopharma INC | $25.39 | 2024 | Mektovi, Tukysa, Braftovi |
| Curium US LLC | $25.03 | 2023 | |
| Sumitomo Pharma America, INC. | $23.79 | 2024 | Orgovyx |
| Glaxosmithkline, LLC. | $23.77 | 2023 | Shingrix |
| Mirati Therapeutics, INC. | $21.51 | 2024 | Krazati |
| Boston Scientific Corporation | $21.04 | 2025 | Therasphere Y90 Glass Microspheres 10 Gbq |
| Ipsen Biopharmaceuticals, INC | $19.58 | 2019 | |
| Genmab U.S., INC. | $18.94 | 2023 | Tivdak |
| Geron Corporation | $17.54 | 2025 | Rytelo |
| Eisai INC. | $14.95 | 2019 | |
| Secura Bio, INC. | $14.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dongxin Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.